Advice
following an abbreviated submission:
fluticasone propionate/formoterol fumarate (flutiform®) is accepted for use within NHSScotland.
Indication under review: the regular treatment of asthma in children aged 5 to 12 years where the use of a combination product (an inhaled corticosteroid and a long-acting β2 agonist) is appropriate:
- for patients not adequately controlled with inhaled corticosteroids and 'as required' inhaled short-acting β2 agonist.
or - for patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist.
SMC has previously accepted fluticasone propionate/formoterol fumarate for use in adults and adolescents aged 12 years and above with asthma where the use of a combination product is appropriate.
Download detailed advice441KB (PDF)
Medicine details
- Medicine name:
- fluticasone/formoterol (Flutiform)
- SMC ID:
- SMC2178
- Indication:
- For the licence extension of low strength flutiform (50/5 µg) in children aged 5 to <12 years. This fixed-dose combination of fluticasone propionate and formoterol fumarate (flutiform inhaler) is indicated in the regular treatment of asthma where the use of a combination product (an inhaled corticosteroid and a long-acting β2 agonist) is appropriate: o For patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short-acting β2 agonist. Or o For patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist. flutiform 50 microgram/5 microgram inhaler is indicated in adults, adolescents and children aged 5 years and above.
- Pharmaceutical company
- Napp Pharmaceuticals Ltd
- BNF chapter
- Respiratory system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 10 June 2019